Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450 www.uspto.gov

JUN 19 2007

Office of Regulatory Policy HFD-7 5600 Fishers Lane (Rockwall II Rm 1101) Rockville, MD 20857

Attention: Beverly Friedman

The attached application for patent term extension of U.S. Patent No. 6,355,245 was filed on May 11, 2007, under 35 U.S.C. § 156.

The assistance of your Office is requested in confirming that the product identified in the application, SolirisTM (Eculizumab), has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period after the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, or a method of manufacturing or use of such a product, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till (Legal Advisor

Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Anita Varma, Esq.

Fish & Neave IP Group Ropes & Gray LLP One International Place

Boston, Massachusetts 02110-2624